vs
Park Hotels & Resorts Inc.（PK）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Park Hotels & Resorts Inc.的1.2倍（$772.1M vs $629.0M），Revvity净利率更高（12.7% vs -32.6%，领先45.3%），Revvity同比增速更快（5.9% vs 0.6%），Revvity自由现金流更多（$161.8M vs $-3.0M），过去两年Revvity的营收复合增速更高（9.0% vs -0.8%）
Park Hotels & Resorts是一家总部位于美国弗吉尼亚州泰森斯的房地产投资信托（REIT），核心业务为酒店物业投资运营。该企业于2017年从希尔顿全球集团分拆成立，在酒店不动产领域拥有专业的投资与管理经验。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
PK vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.2倍
$629.0M
营收增速更快
RVTY
高出5.2%
0.6%
净利率更高
RVTY
高出45.3%
-32.6%
自由现金流更多
RVTY
多$164.8M
$-3.0M
两年增速更快
RVTY
近两年复合增速
-0.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $629.0M | $772.1M |
| 净利润 | $-205.0M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | -26.1% | 14.5% |
| 净利率 | -32.6% | 12.7% |
| 营收同比 | 0.6% | 5.9% |
| 净利润同比 | -410.6% | 3.9% |
| 每股收益（稀释后） | $-1.04 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PKRVTY
| Q4 25 | $629.0M | $772.1M | ||
| Q3 25 | $610.0M | $698.9M | ||
| Q2 25 | $672.0M | $720.3M | ||
| Q1 25 | $630.0M | $664.8M | ||
| Q4 24 | $625.0M | $729.4M | ||
| Q3 24 | $649.0M | $684.0M | ||
| Q2 24 | $686.0M | $691.7M | ||
| Q1 24 | $639.0M | $649.9M |
净利润PKRVTY
| Q4 25 | $-205.0M | $98.4M | ||
| Q3 25 | $-16.0M | $46.7M | ||
| Q2 25 | $-5.0M | $53.9M | ||
| Q1 25 | $-57.0M | $42.2M | ||
| Q4 24 | $66.0M | $94.6M | ||
| Q3 24 | $54.0M | $94.4M | ||
| Q2 24 | $64.0M | $55.4M | ||
| Q1 24 | $28.0M | $26.0M |
毛利率PKRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率PKRVTY
| Q4 25 | -26.1% | 14.5% | ||
| Q3 25 | 9.7% | 11.7% | ||
| Q2 25 | 9.7% | 12.6% | ||
| Q1 25 | 1.1% | 10.9% | ||
| Q4 24 | 13.3% | 16.3% | ||
| Q3 24 | 14.6% | 14.3% | ||
| Q2 24 | 17.6% | 12.4% | ||
| Q1 24 | 14.4% | 6.8% |
净利率PKRVTY
| Q4 25 | -32.6% | 12.7% | ||
| Q3 25 | -2.6% | 6.7% | ||
| Q2 25 | -0.7% | 7.5% | ||
| Q1 25 | -9.0% | 6.4% | ||
| Q4 24 | 10.6% | 13.0% | ||
| Q3 24 | 8.3% | 13.8% | ||
| Q2 24 | 9.3% | 8.0% | ||
| Q1 24 | 4.4% | 4.0% |
每股收益（稀释后）PKRVTY
| Q4 25 | $-1.04 | $0.86 | ||
| Q3 25 | $-0.08 | $0.40 | ||
| Q2 25 | $-0.02 | $0.46 | ||
| Q1 25 | $-0.29 | $0.35 | ||
| Q4 24 | $0.32 | $0.77 | ||
| Q3 24 | $0.26 | $0.77 | ||
| Q2 24 | $0.30 | $0.45 | ||
| Q1 24 | $0.13 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $232.0M | $919.9M |
| 总债务越低越好 | $3.9B | — |
| 股东权益账面价值 | $3.1B | $7.3B |
| 总资产 | $7.7B | $12.2B |
| 负债/权益比越低杠杆越低 | 1.23× | — |
8季度趋势，按日历期对齐
现金及短期投资PKRVTY
| Q4 25 | $232.0M | $919.9M | ||
| Q3 25 | $278.0M | $931.4M | ||
| Q2 25 | $319.0M | $991.8M | ||
| Q1 25 | $233.0M | $1.1B | ||
| Q4 24 | $402.0M | $1.2B | ||
| Q3 24 | $480.0M | $1.2B | ||
| Q2 24 | $449.0M | $2.0B | ||
| Q1 24 | $378.0M | $1.7B |
总债务PKRVTY
| Q4 25 | $3.9B | — | ||
| Q3 25 | $3.9B | — | ||
| Q2 25 | $3.9B | — | ||
| Q1 25 | $3.9B | — | ||
| Q4 24 | $3.9B | — | ||
| Q3 24 | $3.9B | — | ||
| Q2 24 | $3.9B | — | ||
| Q1 24 | $3.8B | — |
股东权益PKRVTY
| Q4 25 | $3.1B | $7.3B | ||
| Q3 25 | $3.4B | $7.4B | ||
| Q2 25 | $3.4B | $7.6B | ||
| Q1 25 | $3.5B | $7.6B | ||
| Q4 24 | $3.6B | $7.7B | ||
| Q3 24 | $3.8B | $7.9B | ||
| Q2 24 | $3.8B | $7.9B | ||
| Q1 24 | $3.8B | $7.8B |
总资产PKRVTY
| Q4 25 | $7.7B | $12.2B | ||
| Q3 25 | $8.8B | $12.1B | ||
| Q2 25 | $8.9B | $12.4B | ||
| Q1 25 | $8.9B | $12.4B | ||
| Q4 24 | $9.2B | $12.4B | ||
| Q3 24 | $9.2B | $12.8B | ||
| Q2 24 | $9.2B | $13.4B | ||
| Q1 24 | $9.1B | $13.4B |
负债/权益比PKRVTY
| Q4 25 | 1.23× | — | ||
| Q3 25 | 1.14× | — | ||
| Q2 25 | 1.12× | — | ||
| Q1 25 | 1.11× | — | ||
| Q4 24 | 1.06× | — | ||
| Q3 24 | 1.03× | — | ||
| Q2 24 | 1.03× | — | ||
| Q1 24 | 1.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $105.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-3.0M | $161.8M |
| 自由现金流率自由现金流/营收 | -0.5% | 21.0% |
| 资本支出强度资本支出/营收 | 17.2% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $102.0M | $509.4M |
8季度趋势，按日历期对齐
经营现金流PKRVTY
| Q4 25 | $105.0M | $182.0M | ||
| Q3 25 | $99.0M | $138.5M | ||
| Q2 25 | $108.0M | $134.3M | ||
| Q1 25 | $86.0M | $128.2M | ||
| Q4 24 | $80.0M | $174.2M | ||
| Q3 24 | $140.0M | $147.9M | ||
| Q2 24 | $117.0M | $158.6M | ||
| Q1 24 | $92.0M | $147.6M |
自由现金流PKRVTY
| Q4 25 | $-3.0M | $161.8M | ||
| Q3 25 | $31.0M | $120.0M | ||
| Q2 25 | $65.0M | $115.5M | ||
| Q1 25 | $9.0M | $112.2M | ||
| Q4 24 | $17.0M | $149.8M | ||
| Q3 24 | $97.0M | $125.6M | ||
| Q2 24 | $66.0M | $136.6M | ||
| Q1 24 | $22.0M | $129.7M |
自由现金流率PKRVTY
| Q4 25 | -0.5% | 21.0% | ||
| Q3 25 | 5.1% | 17.2% | ||
| Q2 25 | 9.7% | 16.0% | ||
| Q1 25 | 1.4% | 16.9% | ||
| Q4 24 | 2.7% | 20.5% | ||
| Q3 24 | 14.9% | 18.4% | ||
| Q2 24 | 9.6% | 19.7% | ||
| Q1 24 | 3.4% | 20.0% |
资本支出强度PKRVTY
| Q4 25 | 17.2% | 2.6% | ||
| Q3 25 | 11.1% | 2.6% | ||
| Q2 25 | 6.4% | 2.6% | ||
| Q1 25 | 12.2% | 2.4% | ||
| Q4 24 | 10.1% | 3.4% | ||
| Q3 24 | 6.6% | 3.3% | ||
| Q2 24 | 7.4% | 3.2% | ||
| Q1 24 | 11.0% | 2.7% |
现金转化率PKRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | 1.21× | 1.84× | ||
| Q3 24 | 2.59× | 1.57× | ||
| Q2 24 | 1.83× | 2.87× | ||
| Q1 24 | 3.29× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PK
| Occupancy | $371.0M | 59% |
| Food And Beverage | $173.0M | 28% |
| Ancillary Hotel | $61.0M | 10% |
| Hotel Other | $24.0M | 4% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
